5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway

Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinohara, Motoko, Shinohara, Mitsuru, Zhao, Jing, Fu, Yuan, Liu, Chia-Chen, Kanekiyo, Takahisa, Bu, Guojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471172/
https://www.ncbi.nlm.nih.gov/pubmed/30934555
http://dx.doi.org/10.3390/ijms20061488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471172/
https://www.ncbi.nlm.nih.gov/pubmed/30934555
http://dx.doi.org/10.3390/ijms20061488

Ejemplares similares